FInAnCIAL PoLICIes For rIsk mAnAGement And tHeIr oBJeCtIves Continued Liquidity risk: continued Less than one year 2009 $000 Cash and cash equivalents 6,428 Accounts receivables 154 other payables 292 6,290 The Company believes that given the Groups forecast operating cash flow during 2011, it has the ability to satisfy its liability commitments.
50. stAFF Costs Hikma Pharmaceuticals PLC currently has eight employees 2009: six excluding Executive Directors : total compensation paid to them amounted toUSD 1,660,000 2009: USD 1,334,000 of which salaries and wages compromise an amount of USD 1,192,000 2009: USD 1,007,000 the remaining balance of USD 468,000 2009: USD 327,000 represent national insurance contributions, the cost of share-based payments and otherbenefits.
51. stoCk oPtIons The details of the stock compensation scheme are provided in Note 36 to the Group accounts.
The number of options granted to the employees ofthe Company including Directors was 2,560,000 2009: 2,560,000 and the total amount of the compensation expenses charged to income statement is USD 24,719 2009: USD 194,600.
LonG-term InCentIve PLAns LtIPs The details of the LTIP scheme are provided in Note 36 to the Group accounts.
The number of awards granted to the employees of the Company including Directors was 721,324 shares 2009: 656,000 and the total amount of the compensation expenses charged to income statement is USD874,022 2009: USD 803,680.
53. sHAre CAPItAL 2010 2009 Issued and fully paid included in shareholders equity $000 $000 193,516,989 2009: 191,627,607 ordinary shares of 10 pence each 34,525 34,236 The details of the issue of the share capital in the year are given in Note 31 to the Group accounts.
